T. Rowe Price Associates, Inc. Acquires 5.4% Stake in Guardant Health Inc (GH)

On May 15, 2026, T. Rowe Price Associates, Inc. filed a Schedule 13G with the SEC, reporting a new ownership stake in Guardant Health Inc (GH). The filing indicates that as of March 31, 2026, the investment adviser beneficially owns 7,035,771 shares of common stock, representing 5.4% of the company's outstanding shares. T. Rowe Price Associates, Inc. reported sole voting power over 6,842,514 shares and sole dispositive power over the full 7,035,771 shares. The filing was made under Rule 13d-1(b), which applies to institutional investment managers acquiring securities in the ordinary course of business without the intent to influence or change the control of the issuer. This filing marks an increase from a previously reported 0.0% position, establishing T. Rowe Price as a significant institutional shareholder in the Palo Alto-based precision oncology company. The total value of the holdings is estimated at approximately $667.8 million based on provided transaction data.